Ziopharm Oncology (ZIOP)

Company Description

ZIOPHARM Oncology (ZIOP) is a second-generation gene therapy company focused on the development of new cancer treatments with a laser focus on the red-hot immune oncology (I/O) sector. ZIOP licensed its gene expression control technology from synthetic-biology innovator Intrexon for use in the development of DNA-based oncology treatments. Under an exclusive channel partner agreement, the two companies have collaborated to develop a tightly controlled system that injects a gene-expression package into tumors to express the anti-tumor cytokine interleukin-12 (IL-12), but only when patients take a pill that contains a ligand to activate the IL-12 gene. When the patient stops taking the pill, IL-12 expression stops, allowing for specific dosing for a set time. Expression is controlled by Intrexon’s proprietary biologic switch known as the RheoSwitch. The ability to administer or withdraw the pill to control gene expression is a key safety benefit.

 

COMPANY ADDRESS
1 First Avenue
Parris Building, #34
Navy Yard Plaza
Boston, MA 02129
United States

COMPANY PHONE
(617) 259-1970

COMPANY WEBSITE


Get BioInvest's perspective on Ziopharm's CEO

Latest Company News

Is ZIOPHARM Oncology Inc (ZIOP) Building Momentum? FLBC News - 5 hours ago The Awesome Oscillator for ZIOPHARM Oncology Inc (ZIOP) is showing a five day consistent downtrend, signaling building market momentum for the shares. [...]
Fri, Aug 18, 2017 11:26:00 PM, Continue reading at the source
Revenue Estimates Analysis Of ZIOPHARM Oncology, Inc. (ZIOP) News Oracle - 15 hours ago Many analysts are providing their Estimated Earnings analysis for ZIOPHARM Oncology, Inc. and for the current quarter 6 analysts have projected that the stock could give an Average Earnings estimate of $-0.14/share. [...]
Fri, Aug 18, 2017 1:50:00 PM, Continue reading at the source
Who Owns ZIOPHARM Oncology Inc (ZIOP)? Simply Wall St - Aug 17, 2017 I am going to take a deep dive into ZIOPHARM Oncology Inc's (NASDAQ:ZIOP) most recent ownership structure, not a frequent subject of discussion among individual investors. These two are the must watch stock's for the fearless investors: ZIOPHARM ... - StockNewsJournal [...]
Thu, Aug 17, 2017 10:30:00 PM, Continue reading at the source
Trading Options During Earnings in ZIOPHARM Oncology Inc CML News - Aug 16, 2017 We're going to examine buying and selling out of the money strangles in ZIOPHARM Oncology Inc and find out once and for all what the winning trades have been during earnings releases. [...]
Wed, Aug 16, 2017 12:56:00 AM, Continue reading at the source
Option Trading: Buy or Sell Straddles in ZIOPHARM Oncology Inc (NASDAQ:ZIOP) CML News - Aug 15, 2017 As we look at ZIOPHARM Oncology Inc we note that deciding whether to buy or sell options (in this case a straddle) is probably the most important question when it comes to option trading. [...]
Tue, Aug 15, 2017 8:15:00 PM, Continue reading at the source
ZIOPHARM Oncology, Inc. (ZIOP) Daily Technical Review & Outlook StockNewsGazette - Aug 14, 2017 ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) gained 1.10% during trading on Friday, going up from its prior closing price of $5.45 to $5.51 The price has been moving in both directions for this period, and there has been a -4.17% loss over 10-day period. ZIOPHARM Oncology Inc (ZIOP) Upgraded to “Hold” at ValuEngine - Sports Perspectives [...]
Mon, Aug 14, 2017 12:22:00 PM, Continue reading at the source
BlackBerry Ltd Stock, Allergan And ZIOPHARM - Top Crossover Trades For Today Amigobulls - Aug 8, 2017 As you can see from the ZIOPHARM Oncology Inc technical chart, 50-day moving average has been acting as a strong resistance to ZIOPHARM stock. [...]
Tue, Aug 08, 2017 6:22:00 AM, Continue reading at the source
Sky's The Limit For Ziopharm Seeking Alpha - Aug 3, 2017 Ziopharm, a Boston based biopharmaceutical company focused on immunotherapies in oncology, presented a corporate update and its second quarter financial results on July 31, 2017. [...]
Thu, Aug 03, 2017 12:45:00 PM, Continue reading at the source
ZIOPHARM Oncology Reports Second Quarter 2017 Financial Results and Provides ... GlobeNewswire (press release) - Jul 31, 2017 BOSTON, July 31, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced its financial results for the second quarter ended June 30, 2017, and provided an ... ZIOPHARM Oncology's (ZIOP) CEO Laurence Cooper on Q2 2017 Results - Earnings ... - Seeking Alpha The ZIOPHARM Oncology Inc (NASDAQ:ZIOP) Set to Announce Earnings on Monday - ExpressNewsline [...]
Mon, Jul 31, 2017 8:03:00 PM, Continue reading at the source
ZIOPHARM Oncology to Host Second-Quarter 2017 Financial Results and Corporate ... Nasdaq - Jul 24, 2017 BOSTON, July 24, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it will host a conference call and webcast slide presentation on Monday, July ... ZIOPHARM Oncology, Inc. (ZIOP) Stock image with current unsupportive move of ... - Stocks Gallery ZIOPHARM Oncology, Inc. (ZIOP) currently has a monthly volatility of 4.30% - StandardOracle [...]
Mon, Jul 24, 2017 10:52:00 AM, Continue reading at the source